Lixin Wan
Overview
Explore the profile of Lixin Wan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
3699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu Z, Sun G, Li J, Zhao J, Wang Z, Qian D, et al.
Cancer Immunol Immunother
. 2025 Mar;
74(4):138.
PMID: 40056201
Background And Aims: This individual patient data pooled analysis aimed to evaluate the effectiveness, safety, and patterns of use of camrelizumab in a large cohort of advanced esophageal cancer (AEC)...
2.
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al.
Nat Med
. 2025 Jan;
PMID: 39843940
Programmed cell death protein-1 (PD-1) inhibitors plus chemotherapy have been the standard of care in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma; however, the survival benefits...
3.
Lu Z, Geng M, Han Y, Cao J, Wang J, Liu T, et al.
Cancer Biol Med
. 2025 Jan;
21(12.
PMID: 39831767
Objective: Esophageal cancer (EC) ranks eighth among cancers in cancer-related deaths globally, and ~44% of new cases occur in China. We sought to describe the clinical characteristics and treatment landscape...
4.
Riley A, Grant M, Snell A, Cromwell E, Vichas A, Moorthi S, et al.
iScience
. 2024 Aug;
27(8):110499.
PMID: 39161959
is a rare and understudied oncogene in lung cancer. Despite structural similarity to other RAS GTPase proteins such as KRAS, oncogenic RIT1 activity does not appear to be tightly regulated...
5.
Duan Q, Huang H, Zhang S, Wang Y, Lu D, Wan L, et al.
Front Nutr
. 2024 Jun;
11:1389714.
PMID: 38840700
Background: The high prevalence of kidney stones in adults worldwide has prompted research into potential interventions, one of which involves exploring the consumption of antioxidants that may confer protective effects....
6.
Jia R, Shan T, Zheng A, Zhang Y, Lu P, Zhang G, et al.
J Clin Oncol
. 2024 May;
42(20):2436-2445.
PMID: 38710003
Purpose: This phase 3 trial aimed to compare the efficacy and safety of capecitabine or capecitabine plus oxaliplatin (XELOX) with those of fluorouracil plus cisplatin (PF) in definitive concurrent chemoradiotherapy...
7.
Liu X, Gillis N, Jiang C, McCofie A, Shaw T, Tan A, et al.
PLoS Comput Biol
. 2024 Feb;
20(2):e1011873.
PMID: 38335222
Super enhancers (SE), large genomic elements that activate transcription and drive cell identity, have been found with cancer-specific gene regulation in human cancers. Recent studies reported the importance of understanding...
8.
Yin T, Wang G, Wang L, Mudgal P, Wang E, Pan C, et al.
Nat Immunol
. 2024 Jan;
25(2):268-281.
PMID: 38195702
Melanoma cells, deriving from neuroectodermal melanocytes, may exploit the nervous system's immune privilege for growth. Here we show that nerve growth factor (NGF) has both melanoma cell intrinsic and extrinsic...
9.
Riley A, Grant M, Snell A, Vichas A, Moorthi S, Urisman A, et al.
bioRxiv
. 2023 Dec;
PMID: 38077017
is a rare and understudied oncogene in lung cancer. Despite structural similarity to other RAS GTPase proteins such as KRAS, oncogenic RIT1 activity does not appear to be tightly regulated...
10.
Shang F, Cao Y, Wan L, Ren Z, Wang X, Huang M, et al.
mBio
. 2023 Oct;
14(6):e0153123.
PMID: 37846989
This is the first clinical research to systematically expound the difference between gastric cancer (GC) individuals with and GC individuals without from the perspective of multi-omics. This clinical study identified...